Literature DB >> 29332089

Gene Therapy for Parkinson's Disease.

Vivek Sudhakar, R Mark Richardson.   

Abstract

Gene therapy is a clinical tool that may eventually provide therapeutic benefit to patients suffering from movement disorders through a few potential mechanisms: direct correction of the pathogenic mechanism, neuroprotection, neurorestoration or symptom control. The therapeutic mechanism is therefore dependent on knowledge of disease pathogenesis and the required temporal and spatial specificities of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces. Although critical clinical work is ongoing to optimize the direct intracerebral delivery of transgenes to the brain, the field has recently entered a new technological era, where interventional-MRI-guided convection-enhanced delivery is the gold standard for verifying accurate vector delivery in real-time.
© 2018 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2018        PMID: 29332089     DOI: 10.1159/000481109

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  2 in total

Review 1.  LRRK2 and Proteostasis in Parkinson's Disease.

Authors:  María Dolores Pérez-Carrión; Inmaculada Posadas; Javier Solera; Valentín Ceña
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

Review 2.  Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease.

Authors:  R Mark Richardson; Krystof S Bankiewicz; Chadwick W Christine; Amber D Van Laar; Robert E Gross; Russell Lonser; Stewart A Factor; Sandra K Kostyk; Adrian P Kells; Bernard Ravina; Paul S Larson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-07-30       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.